Lupin gets USFDA’s observations for Pithampur Unit-2 manufacturing facility

31 Mar 2023 Evaluate

United States Food and Drug Administration (USFDA) has inspected Lupin’s Pithampur Unit-2 manufacturing facility from March 21 to March 29, 2023. The inspection closed with issuance of a Form-483 with ten observations.

The company is addressing the observations comprehensively and will work with the USFDA to resolve these issues at the earliest. The company has uphold quality and compliance with utmost importance across all its facilities. 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2176.25 -18.75 (-0.85%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×